BOSTON (Reuters) - Small doses of Astellas Pharma Inc’s Prograf did a better job at preventing rejection of a transplanted kidney than varying doses of other drugs including a low dose of Wyeth’s Rapamune, researchers said on Wednesday.The research, published in Thursday’s New England Journal of Medicine, is part of an effort to reduce the side effects of anti-rejection drugs like cyclosporine, which can damage the kidney with long-term use.
